# Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia

> **NCT00390897** · PHASE4 · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 360 (—)

## Conditions studied

- Chronic Myeloid Leukaemia

## Interventions

- **DRUG:** Glivec
- **DRUG:** Interferon

## Key facts

- **NCT ID:** NCT00390897
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2006-10
- **Final completion:** 2007-12
- **Target enrollment:** 360 (—)
- **Last updated:** 2008-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00390897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00390897, "Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00390897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*